Study of Absorption Characteristics of Two Multivitamin Mineral Formulations (Gel vs. Tablet/Capsule)

Galilee CBR20 enrolled

Overview

This clinical study is designed to evaluate difference in the AUC of the absorption of Multivitamin and minerals defined in the protocol

This clinical study is designed to evaluate difference in the AUC of the absorption of Multivitamin and minerals: 1. Tablet/capsule administration - up to 20 healthy volunteers will be recruited to the study. The tablet/capsule will be administered as a single dose after 12 hours of fasting. The participants will be monitored during 6 hours for the level of minerals and Multivitamin minerals in the blood, adverse events and vital signs. 2. Gel administration - the gel will be administrated to the same group of patients in the single dose after 12 hours of fasting. The participants will be monitored during 6 hours for the level of minerals and Multivitamin minerals in the blood, adverse events and vital signs.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Enrollment

Conditions

Vitamin Deficiency

Interventions

MultivitaminsDIETARY_SUPPLEMENT

After the study product administration blood tests will be performed in order to calculate the AUC for each mineral and vitamin - Vit A Vit E Folic Acid Vit C Calcium Magnesium After the washout period, the same procedure will be done for the additional formulation of the multivitamins.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy male or female and aged 18-65 years * BMI - 19-24 * Subject is not pregnant and is not nursing * Signed Informed Consent Form Exclusion Criteria: * Current use of multivitamin or mineral complexes (washout of 4 days before Visit 2 is permitted) * Participants with known vitamins or mineral deficiencies * Diabetes Type II * Smoking * Subjects who have undergone surgery within the last 3 months. * Subjects with a clinically significant (during last 3 months) infectious, immune-mediated or active malignant disease. * Subjects who are receiving an elemental diet or parenteral nutrition. * Subjects who are treated with insulin. * Women with childbearing potential unless surgically sterile or using adequate contraception (either IUD, oral or Depo-provera contraceptive, or barrier plus spermicide); pregnant or breastfeeding mothers. * Subjects who will be unavailable for the duration of the trial, who are unlikely to be compliant with the protocol, or who are felt to be unsuitable by the Investigator for any other reason. * Known sensitivity to any ingredients in the study product * History of addiction or drug abuse * Alcoholic regular use

Locations (1)

Israel

Tel Aviv, Central District, Israel

Outcomes

Primary Outcomes

Mean fractional absorption

A comparison of mean fractional absorption of the two Multivitamin mineral formulations (gel vs. tablet/capsule).

Time frame: 6 hours

Secondary Outcomes

Absorption rate

A comparison of absorption rate across the two Multivitamin mineral formulations (gel vs. tablet/capsule).

Time frame: 6 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.